Epic Sciences Overview

  • Founded

  • 2008

Founded
  • Status

  • Private

  • Employees

  • 135

Employees
  • Latest Deal Type

  • Series F

  • Latest Deal Amount

  • $43M

  • Investors

  • 22

Epic Sciences General Information

Description

Developer of diagnostic tests technology intended for quick and non-invasive detection of genetic and molecular changes in cancer throughout. The company's technology assesses the number of circulating tumor cells and their subtypes, profiles single-cell phenotype and genotype as well as provide near real-time information about each different cellular population before and after treatments with no cell left behind, enabling oncologists to identify and analyze rare disease cells from a tube of blood that also contains millions of normal cells.

Contact Information

Website
www.epicsciences.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Decision/Risk Analysis
Primary Office
  • 9381 Judicial Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Epic Sciences Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epic Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series F) 29-Apr-2022 $43M 00000 00000 Completed Generating Revenue
13. Secondary Transaction - Private 01-Feb-2021 00000 Completed Generating Revenue
12. Debt - PPP 14-Apr-2020 00.000 00000 Completed Generating Revenue
11. Later Stage VC (Series E) 12-Sep-2018 0000 00000 00000 Completed Generating Revenue
10. Debt - General 01-Aug-2017 0000 00000 Completed Generating Revenue
9. Later Stage VC (Series D) 28-Apr-2017 0000 00000 0000 Completed Generating Revenue
8. Later Stage VC (Series C1) 23-May-2016 00.000 0000 000.00 Completed Generating Revenue
7. Debt - General 01-Jun-2015 0000 000.00 Completed Generating Revenue
6. Later Stage VC (Series C) 30-Jul-2014 $30M $47.3M 000.00 Completed Generating Revenue
5. Early Stage VC (Series B) 13-Nov-2012 $13M $17.3M 000.00 Completed Generating Revenue
To view Epic Sciences’s complete valuation and funding history, request access »

Epic Sciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series F-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series F-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series B1 16,003,560 $0.000100 8% $0.56 $0.56 1x $0.56 4.37%
Series A1 6,050,104 $0.000100 8% $0.28 $0.28 1x $0.28 1.65%
To view Epic Sciences’s complete cap table history, request access »

Epic Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of diagnostic tests technology intended for quick and non-invasive detection of genetic and molecular changes
Biotechnology
San Diego, CA
135 As of 2023
00000
0000 0000-00-00
00000000000 00000

000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000000000 000000000
Beverly, MA
00 As of 0000
00.00
0000000000 0 00.00

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000000 000000
Houston, TX
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epic Sciences Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genomic Expression Venture Capital-Backed Beverly, MA 00 00.00 0000000000 0 00.00
0000000 Venture Capital-Backed Houston, TX 00 00000 0000000000 0 00000
00000000 Formerly VC-backed Austin, TX 000 000.00 000000&0 000.00
0000000 Venture Capital-Backed Irvine, CA 000 00000 00000000
00000000 000000000 Formerly VC-backed Seattle, WA 000 00000 00000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Epic Sciences Patents

  • 126

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 11

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Epic Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018275265-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000
CA-3065316-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000
EP-3631445-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000
EP-3631445-A4 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000 0
US-20220260574-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 G01N33/57434
To view Epic Sciences’s complete patent history, request access »

Epic Sciences Executive Team (23)

Name Title Board Seat Contact Info
W. Lloyd Sanders President, Chief Executive Officer & Board Member
Jason Christiansen Ph.D Chief Technology Officer
Peter Kuhn Ph.D Co-Founder & Chief Scientific Advisor
Dena Marrinucci Ph.D Co-Founder & Clinical Advisory Board Member
Jorge Nieva Co-Founder
You’re viewing 5 of 23 executive team members. Get the full list »

Epic Sciences Board Members (13)

Name Representing Role Since
Andrew ElBardissi MD Deerfield Management Board Member 000 0000
Charles Kennedy MD Blue Ox Healthcare Partners Board Member 000 0000
Gregory Critchfield MD Self Board Member 000 0000
Gregory Lucier Self Chairman 000 0000
James Rothman Ph.D Arsenal Capital Partners Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Epic Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epic Sciences Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Arsenal Capital Partners PE/Buyout Minority 000 0000 000000 0
ATEM Capital Venture Capital Minority 000 0000 000000 0
Blue Ox Healthcare Partners Growth/Expansion Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Labcorp Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 22 investors. Get the full list »

Ready to get started?

Request a free trial